Industry Non-CME (INC) Programming
Discover exciting industry innovations during sponsored events throughout the 2026 AAD Annual Meeting.
The Industry Non-CME (INC) Programs at the 2026 AAD Annual Meeting are your chance to learn about the latest innovations directly from industry. At the sponsoring company’s discretion, these sessions present new research findings, showcase specialty innovations, conduct demonstrations, and host lively discussions.
Pre-registration is required, and food and beverage are provided by the sponsoring company. INC Programs take place in the evening after education sessions and are exclusively developed and delivered by the sponsor. They do not qualify for continuing medical education credit.
The full agenda for the INC Programs is available below and online. Be sure to check out the stimulating sessions, topics, and speakers lined up for the event. Please note: There will be no sessions Friday, March 27.
View Industry Product Theater sessions here.
Thursday, March 26, 2026
IL-23 Innovation: New Data Addressing Plaque Psoriasis
Sponsor: Johnson and Johnson
Overview: Join us for an engaging and compelling program exploring innovations in targeting the IL-23 pathway and new data shaping the treatment of plaque psoriasis. This session will review the science behind IL-23–targeted therapies and their role in addressing unmet needs across patient populations. Faculty will discuss select safety and efficacy data and potential impact on clinical decision-making as well as offer practical perspectives on treatment selection and prescribing considerations in today’s evolving plaque psoriasis landscape.
Speakers: April W. Armstrong, MD, MPH; Jason Hawkes, MD, MS; G. Michael Lewitt, MD, FAAD; Bruce Strober, MD, PhD
6:30 p.m. Registration | 7 p.m. Program
Embassy Suites Denver Convention Center – Crystal Ballroom
Register: https://forms.office.com/pages/responsepage.aspx?id=XCxh-ZiFl0isR4SoAI9UiGJiyBun2ZpFuVqAOEz2QOhUMTNNRFRCTkdMRE85MkZTUk45VzZITFdORC4u&route=shorturl
A Seat at the HS Expert’s Table: A Master Class in Diagnosis and Treatment Advances for Hidradenitis Suppurativa
Sponsor: Decera Clinical Education in partnership with the HS Foundation; Supported by educational grants from Incyte Corporation, Novartis Pharmaceuticals Corporation, and UCB Inc.
Overview: This expert-led masterclass will bring together leading health care professionals to explore the latest advances in the diagnosis and management of hidradenitis suppurativa (HS). Participants will gain actionable, evidence-based strategies to improve patient outcomes across the full HS disease spectrum. Through small group, expert-facilitated breakout sessions, attendees will engage in peer-to-peer discussion and debate while also experiencing close collaboration and guidance from expert faculty. In partnership with HS Foundation, Decera Clinical Education is pleased to incorporate patient cases and patient perspective videos throughout the educational content.
Speakers: Leandra Barnes, MD; Katrina Hana Lee, MD; Mikael Kevork Horissian, MD; Venessa Peña-Robichaux, MD
6:30 p.m. Registration | 7 p.m. Program
Embassy Suites Denver Convention Center – Silverton Ballroom
Register: www.deceraclinical.com/education/HSExpertTable2026
Saturday, March 28, 2026
Unlocking the Potential of OX40 Ligand Pathway in AD: Targeting the Inflammatory Prequel
Sponsor: Sanofi
Overview: In this industry-supported, non-CME program, Dr. Eric Simpson, Dr. Alexandra Golant, and Dr. Peter Lio will guide an interactive investigative quest focused on the OX40 ligand pathway in atopic dermatitis (AD). This unique symposium format integrates interactive challenges, progressively unveiling insights across key thematic modules. The program will dive deep into unmet needs in the heterogeneous population of patients with AD, highlighting the role of the OX40 ligand pathway in the underlying pathophysiology of AD, and why targeting the inflammatory prequel is important. Our experts will also explore the newly available phase 3 data for amlitelimab. This program will emphasize the role of the OX40 ligand pathway and how targeted therapies could potentially bridge the treatment gap for patients with AD.
Speakers: Alexandra Golant, MD; Peter Lio, MD; Eric Simpson, MD, MCR
6:30 p.m. Registration | 7 p.m. Program
Embassy Suites Denver Convention Center – Crystal Ballroom
Cracking the Code: Diagnosing and Managing Skin Diseases with Type 2 Inflammation
Sponsor: Sanofi Regeneron
Overview: This two-hour educational program delves into the pivotal role of type 2 inflammation in diverse skin conditions, including atopic dermatitis, bullous pemphigoid, chronic spontaneous urticaria, and prurigo nodularis. It will highlight both shared and distinct disease mechanisms and patient burdens, providing crucial insights for optimizing clinical management strategies. Experts will guide the audience through diverse patient cases to illuminate diagnostic nuances and the pathophysiology of each condition. These cases will also highlight the importance of shared decision-making and the broadening of treatment goals beyond symptom control. Dynamic panel discussion and active audience participation will be facilitated through real-time polling and curated Q&A sessions.
Speakers: Donna Culton, MD, PhD; Lawrence Eichenfield, MD; Sarina Elmariah, MD, PhD, MPH; Jason Hawkes, MD, MS
6:30 p.m. Registration | 7 p.m. Program
Embassy Suites Denver Convention Center – Cripple Creek Ballroom
Vitiligo, Clearly: Myths, Mechanisms, and What’s Next
Sponsor: Pfizer
Overview: This symposium is an in-depth exploration of vitiligo designed to debunk common myths and misperceptions of the disease. It will dive into the multifaceted world of vitiligo, bringing together leading experts to discuss evidence-based understanding of vitiligo as an autoimmune disease, current treatment options, future therapeutic targets, and the meaningful impact on a patient’s quality of life.
Speakers: Dr. Viktoria Eleftheriadou; Dr. Khaled Ezzedine; Dr. Iltefat Hamzavi; Dr. David Rosmarin
6:30 p.m. Registration | 7 p.m. Program
Embassy Suites Denver Convention Center – Silverton Ballroom
Register: TBD
Sunday, March 29, 2026
Transforming the Care of Psoriatic disease: The Role of Overweight and Obesity-Related Inflammation
Sponsor: Lilly USA, LLC
Overview: This medical discussion program will explore the relationship between psoriatic disease and overweight or obesity, with a focus on clinical evidence and practical management considerations. The program will:
- Understand the unmet medical needs of patients with psoriatic disease who also have overweight or obesity
- Learn how psoriatic disease and overweight or obesity each contribute to systemic inflammation
- Review the latest scientific evidence on the impact of obesity therapies in managing psoriatic disease among patients with overweight or obesity
- Identify therapeutic approaches to address overweight or obesity in psoriatic disease and strategies for clinical discussion
Speakers: April Armstrong, MD, MPH; Brad Glick, DO, MPH; Mark Lebwohl, MD
6:30 p.m. Registration | 7 p.m. Program
Embassy Suites Denver Convention Center – Crystal Ballroom
Navigating the Psychosocial Impact of Dermatologic Disease: The Patient Journey
Sponsor: Medscape Live; Supported by AbbVie Inc
Overview: Breakthrough Learning: Patient-Centered Dermatology Care
Step beyond traditional learning and into the real world of patient-centered dermatology. This groundbreaking program puts you at the intersection of clinical expertise and authentic patient experiences — equipping you with insights and strategies that will reshape how you care for your patients with atopic dermatitis, alopecia areata, and vitiligo. Dive into three powerful case studies through immersive, small-group Patient Journey Stations that mirror real-world practice. In partnership with the National Eczema Association, National Alopecia Areata Foundation, and Global Vitiligo Foundation, you’ll:
- Hear authentic patient voices
- Engage directly with faculty and colleagues to exchange ideas
- Ask questions in an informal setting
- Experience dynamic live panel discussions that bridge patient perspectives with clinical excellence
Seize this unique opportunity to elevate your clinical practice!
Speakers: Seemal R. Desai, MD, FAAD (moderator); Tina Bhutani, MD, MAS; Mona Shahriari, MD, FAAD
6:30 p.m. Registration | 7 p.m. Program
Embassy Suites Denver Convention Center – Silverton Ballroom
Register: https://www.medscape.org/sympo/derm-condition-burden
Dermatology Meets Rheumatology: Tackling CLE Together
Sponsor: Biogen
Overview: This interactive two-hour scientific symposium integrates dermatology and rheumatology perspectives to provide a comprehensive review of cutaneous lupus erythematosus (CLE) as a distinct clinical and immunologic disease. The program will examine CLE classification, histopathologic features, epidemiology, progression to scarring and systemic lupus erythematosus (SLE), and evidence-based models of multidisciplinary co-management. Emerging insights into CLE pathogenesis, interferon biology, and plasmacytoid dendritic cell–driven inflammation will be discussed alongside clinical trial data from phase 1 and phase 2 LILAC studies, including validated and novel outcome measures. Emphasis will be placed on translating mechanistic and clinical trial endpoints into meaningful clinical decision-making, with review of ongoing phase 3 AMETHYST study design. Audience engagement through structured polling will support real-time assessment of practice patterns and knowledge gaps.
Speakers: Karen Costenbader, MD, MPH; Ruth Ann Vleugels, MD, MPH, MBA; Natalie Wright, MD
6:30 p.m. Registration | 7 p.m. Program
Hyatt Regency – Centennial Ballroom BC
